



**Australian**  
**Thursday 26/03/2009**

Page: 20  
Section: Business News  
Region: Australia, AU  
Circulation: 137000  
Type: National  
Size: 75.68 sq.cms.



**slice**  
slicemedia.com

press clip

## Health firm gets a lending fund boost

Health

DIAGNOSTICS developer HealthLinx has secured a new funding facility of up to \$3 million from its largest shareholder, the Copulos Group.

HealthLinx managing director Nick Gatsios said the facility would enable the company to pursue current initiatives unhindered.

“Our major shareholder understands this business and its near-term potential value,” Mr Gatsios said.

“In light of the funding difficulties facing many Australian biotech companies, this is a superb outcome for HealthLinx.”

Drawdowns from the debt facility are available over the next three years. They will be interest-bearing at 12.5 per cent per annum.

At the lender’s election, the drawdowns can be converted into ordinary shares in the company at 80 per cent of the volume-weighted average price over the five trading days prior to the notice of conversion.

The managing director of the Copulos Group, Stephen Copulos, is a non-executive director of HealthLinx.

HealthLinx has developed an early-stage ovarian cancer diagnostic, OvPlex, which is on the market in Australia.

HealthLinx shares closed up 0.3 cents at 5.8c.

AAP